Current issue

  • Select all
    |
  • GUO Yin-feng, ZHUANG Yu-qing, HUANG Guo-yuan, DU Ling-ran
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Virtual screening is a critical procedure for identifying potential hit compounds in the early stage of drug research and development. Among structure-based virtual screening approaches, molecular docking is the most extensively applied technique. It simulates the binding modes between ligands and target proteins via search algorithms and scoring functions, and evaluates binding affinity to predict the potential bioactivity of compounds. With the rapid advancement of technologies including computer-aided drug design and artificial intelligence-aided drug design, the efficiency of drug virtual screening has been significantly improved, while research costs have been substantially reduced and the development cycle shortened. This article systematically summarizes the fundamental principles, advantages, disadvantages and applicable scenarios of current mainstream molecular docking software, and focuses on reviewing typical application cases of such methods in the field of anti-infection, aiming to provide reference for researchers to rationally select appropriate molecular docking tools.
  • WANG Yan-yan, ZHU Hui, FAN Wei-bin
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To construct a thermosensitive Poloxamer 407 hydrogel delivery system loaded with artificial musk-borneol composite, characterize its physicochemical properties, evaluate its promoting effect on wound repair in mice with pressure ulcers, and preliminarily elucidate the molecular mechanism underlying its dual-pathway synergistic regulation of "anti-inflammation and pro-angiogenesis". Methods: The poloxamer 407/musk-borneol composite hydrogel was prepared by the cold dissolution method, and characterized with respect to gelation time, swelling ratio, in vitro drug release profile and degradation properties. A pressure ulcer model was established in C57BL/6J mice via the ischemia-reperfusion method. The model mice were randomly divided into a control group, a blank hydrogel group and a drug-loaded hydrogel group (drug-loaded group). The wounds were covered with normal saline gauze, blank hydrogel and drug-loaded hydrogel respectively, with dressing change once daily for 14 consecutive days. Mice in each group were sacrificed on day 7 and day 14 of intervention, respectively. The wound repair effect and molecular regulation mechanism of the composite hydrogel were evaluated by techniques including wound healing rate measurement, HE staining, Masson's trichrome staining, immunohistochemistry and Western blotting. Results: The prepared composite hydrogel had a gelation time of (25±3) s at 37 ℃, a swelling ratio of 285%±12%, and a 72-hour cumulative drug release rate of 82.4%±3.1%. Animal experiments showed that on day 7 of intervention, the wound healing rate of the drug-loaded group reached 68.4%±5.2%, which was significantly higher than that of the blank hydrogel group (52.1%±4.3%) and the control group (36.7%±3.8%) (P<0.01). HE staining revealed that inflammatory cell infiltration in the drug-loaded group was markedly reduced compared with the control group. Masson's trichrome staining showed that collagen fibers were arranged significantly more regularly in the drug-loaded group than in the control group. Immunohistochemical results indicated that the mean optical density of CD34+ positive expression in the drug-loaded group was significantly higher than that in the control group (0.478±0.115 vs 0.372±0.128, P<0.05). The protein expression level of VEGF in the drug-loaded group was significantly upregulated compared with the control group (P<0.05). Western blotting results showed that the p-p65/β-actin ratio in the drug-loaded group decreased by 42% relative to the control group, while the p-PI3K/PI3K ratio and p-Akt/Akt ratio increased by 1.8-fold and 1.6-fold, respectively. Conclusion: The thermosensitive poloxamer 407/musk-borneol composite hydrogel possesses good thermosensitive sustained-release properties. It regulates the wound microenvironment through the dual-axis synergistic mechanism of "anti-inflammation and pro-angiogenesis", namely alleviating inflammatory response by inhibiting the NF-κB pathway and promoting angiogenesis by activating the PI3K/Akt pathway, which provides a novel therapeutic strategy for the intelligent repair of pressure ulcers.
  • CHEN Jia-zhi, ZHENG Zhi-ming, YAN Meng-qiu
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process of anti-infective therapy in a patient with severe pneumonia complicated with augmented renal clearance (ARC) induced by bacterial-viral co-infection, and to provide reference for the rational clinical use of antibacterial agents in patients with ARC. Methods and Results: A 36-year-old female patient was hospitalized for "fever, dyspnea and hemoptysis for 3 days". The admission diagnoses included severe pneumonia, hemoptysis of undetermined etiology, type Ⅰ respiratory failure and hypokalemia. The patient was admitted to the intensive care unit (ICU) for monitoring and management. Empirical anti-infective therapy with imipenem-cilastatin sodium plus levofloxacin was initiated, accompanied by comprehensive pathogenic tests and influenza virus screening. On day 2 of treatment, the six-panel respiratory virus nucleic acid assay tested positive for influenza B virus, and oseltamivir capsules were added for antiviral treatment. On day 3 of treatment, sputum culture confirmed the presence of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum β-lactamase-producing Escherichia coli. Next-generation sequencing of bronchoalveolar lavage fluid detected Staphylococcus aureus, Pseudomonas aeruginosa and influenza B virus, and blood culture indicated Gram-positive cocci infection. Accordingly, vancomycin (1 g, q12h) was administered for MRSA coverage, levofloxacin was discontinued, and therapeutic drug monitoring of vancomycin was performed. On day 5 of treatment, blood culture verified MRSA infection. The first measured vancomycin trough concentration (4.10 μg/mL) was well below the target therapeutic window. The clinical pharmacist recommended adjusting the vancomycin dosage to "1 g, q8h". On day 10 of treatment, the vancomycin trough concentration reached 9.59 μg/mL, and the pharmacist suggested a further dosage adjustment to "1 g, q6h". On day 12 of treatment, given that the patient had completed a full course of oseltamivir but achieved unsatisfactory viral clearance, oseltamivir was switched to baloxavir marboxil tablets. On day 13 of treatment, the patient's body temperature normalized, with marked improvement in clinical symptoms and signs. The patient was discharged in improved condition on day 17 of treatment. Conclusion: For patients with severe infection complicated with ARC, timely identification of ARC status and implementation of individualized dose adjustment by clinical pharmacists based on therapeutic drug monitoring and creatinine clearance assessment are critical to ensuring that vancomycin achieves effective target concentrations and improves clinical outcomes.
  • YUAN Jing, WANG Ying, NI Sheng-jie
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the antifungal treatment process and pharmaceutical care practice in a patient with acquired immunodeficiency syndrome (AIDS) complicated by Talaromyces marneffei infection, and to provide reference for the rational clinical use of antifungal agents and the management of drug interactions. Methods and Results: A 23-year-old male patient, who had not received regular antiviral therapy after AIDS diagnosis, was admitted for "cough for 10 days accompanied by fever for 5 days". Empirical antifungal therapy with fluconazole was initiated after admission. Talaromyces marneffei infection was subsequently confirmed by bone marrow culture, and the clinical pharmacist recommended switching from fluconazole to voriconazole. The patient's body temperature gradually normalized after the regimen adjustment, but severe liver injury developed 6 days after voriconazole administration. The clinical pharmacist suggested discontinuing potentially hepatotoxic drugs. Accordingly, trimethoprim-sulfamethoxazole, voriconazole and anti-human immunodeficiency virus (anti-HIV) agents were withdrawn, and hepatoprotective and jaundice-alleviating therapy was intensified. Six days after drug discontinuation, the patient's liver function improved significantly. Voriconazole was reintroduced thereafter, with no recurrence of severe liver injury. The patient was finally discharged in stable condition and continued maintenance therapy with voriconazole after discharge. Conclusion: Talaromyces marneffei infection is a severe opportunistic infection in patients with AIDS. Voriconazole serves as an effective alternative for patients intolerant to amphotericin B, but its risk of liver injury cannot be overlooked. It is recommended to strengthen liver function monitoring in patients with underlying hepatic dysfunction or receiving multiple concomitant medications, and to suspend suspected agents plus administer hepatoprotective supportive therapy when necessary. Clinical pharmacists play a critical role in optimizing antifungal regimens, identifying drug interactions, and providing early warning and management of liver injury.
  • LIU Ping-feng, QIAN Xin
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the diagnosis and treatment process of cholestatic drug-induced liver injury (DILI) induced by tigecycline in a patient with severe acute pancreatitis, and to provide reference for the safe clinical use of tigecycline as well as the identification and management of such adverse drug reactions. Methods and Results: A 57-year-old male patient was admitted for "persistent pain in the left middle abdomen for over 16 hours" and diagnosed with severe acute pancreatitis. After admission, tigecycline combined with ampicillin-sulbactam sodium was initiated for anti-infective therapy for concomitant Acinetobacter baumannii infection. After approximately 11 days of treatment, mild abnormalities in liver function parameters were detected, with alanine aminotransferase (ALT) at 110 U/L and total bilirubin (TBil) at 24.5 μmol/L. Tigecycline was discontinued immediately, but the liver injury continued to worsen after drug withdrawal, accompanied by mild scleral icterus. Following multidisciplinary consultation, ampicillin-sulbactam sodium was discontinued and switched to meropenem for anti-infective treatment, and polyene phosphatidylcholine combined with ademetionine 1, 4-butanedisulfonate was administered for hepatoprotective therapy. After drug cessation and targeted intervention, the patient's liver function parameters gradually improved, the infection was effectively controlled, and the patient was finally discharged uneventfully. Conclusion: Tigecycline can induce cholestatic DILI, and liver function may continue to deteriorate even after drug withdrawal, which necessitates close monitoring. The participation of clinical pharmacists in the evaluation and adjustment of pharmacotherapeutic regimens facilitates early identification of adverse drug reactions, optimization of individualized treatment plans, and assurance of medication safety in critically ill patients.
  • YANG Lian-ying, YANG Lin, XIA Zhuo-wei
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the clinical characteristics of antibacterial agent-related adverse drug reactions (ADRs) in perioperative patients with hip fractures, and to provide reference for safe clinical medication use. Methods: Medical records of 88 patients with hip fractures who developed antibacterial agent-related ADRs during the perioperative period, admitted to Fengcheng Hospital of Traditional Chinese Medicine from January 2024 to June 2025, were collected as research data. Clinical information including gender, age, fracture type, surgical procedure, categories and administration routes of antibacterial agents involved in ADRs, involved systems/organs and corresponding clinical manifestations, and clinical outcomes were extracted to analyze the occurrence patterns of antibacterial agent-related ADRs. Results: Among the 88 patients with ADRs, the majority were aged over 60 years (70 cases, 79.55%). Femoral neck fracture was the predominant fracture type (50 cases, 56.82%), and internal fixation was the main surgical procedure (52 cases, 59.09%). Cephalosporins (51 cases, 57.95%) and quinolones (25 cases, 28.41%) accounted for most of the ADR-related antibacterial agents, and all agents were administered via the intravenous route. The ADRs involved 4 systems, among which skin and skin appendage disorders were the most common (49 cases, 55.68%), mainly manifesting as scattered erythematous rashes with severe pruritus. After ADRs were confirmed, all suspected antibacterial agents were immediately discontinued, and targeted interventions were performed according to ADR severity and patients' clinical manifestations. Among them, 82 patients (93.18%) achieved symptom relief or resolution within 3 days after drug discontinuation and were judged as cured; the remaining 6 patients (6.82%) showed significant symptom improvement within 1 week and were judged as improved. The overall prognosis of patients was good. Conclusion: Antibacterial agent-related ADRs in perioperative patients with hip fractures predominantly occur in elderly patients. Cephalosporins and quinolones are the main causative agents, and skin and skin appendage damage is the primary clinical manifestation. Clinical attention should be focused on the above high-risk agents, and comprehensive interventions should be strengthened to ensure medication safety of patients.
  • QIN Wan-zhao, HE Guang-yao
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To predict the potential targets and signaling pathways of 14-thienyl methylene matrine (YYJ18), a matrine derivative, against Epstein-Barr virus (EBV) infection based on network pharmacology and molecular docking, and to provide a theoretical basis for subsequent research on its anti-EBV mechanism and drug development. Methods: The SMILES string of YYJ18 was retrieved from the PubChem database, and its potential targets were predicted via SwissTargetPrediction, SuperPred, SEA and NetInfer databases, respectively. EBV infection-related targets were collected from GeneCards, OMIM and DisGeNET databases using the keyword "Epstein-Barr virus infections". The intersection of the two target sets was obtained as common targets. A protein-protein interaction (PPI) network was constructed through the STRING database, and topological analysis and core target screening were performed using Cytoscape software. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted on the Weishengxin online platform. A "disease-pathway-target-drug" multi-level network was further established. Finally, molecular docking validation of YYJ18 with core targets was carried out on the CB-DOCK2 platform. Results: A total of 255 potential targets of YYJ18 and 3,124 EBV infection-related targets were identified, with 87 intersection targets. 18 core targets were screened from the PPI network, including PIK3R1, STAT3 and HSP90AA1. GO enrichment analysis revealed that biological processes mainly involved response to drug, response to peptide hormone, protein autophosphorylation and cellular response to polypeptide; cellular components mainly included membrane rafts, membrane microdomains, membrane regions and transferase complexes; molecular functions mainly covered protein serine/threonine kinase activity, protein tyrosine kinase activity and non-transmembrane protein tyrosine kinase activity. KEGG pathway enrichment analysis indicated that targets were predominantly enriched in the PD-L1/PD-1 pathway, PI3K-Akt signaling pathway and NF-κB signaling pathway. The constructed "disease-pathway-target-drug" network contained 42 EBV infection gene targets and 10 signaling pathway nodes. The potential key targets included NFKB1, CHUK and PIK3R1, and the core signaling pathways comprised the chemokine signaling pathway, HIF-1 signaling pathway and PD-L1/PD-1 pathway. Molecular docking results showed that YYJ18 could form stable binding conformations with all the above core targets, with good binding affinity. Conclusion: The matrine derivative YYJ18 may exert potential anti-EBV infection effects by acting on multiple core targets such as PIK3R1, STAT3 and HSP90AA1, and synergistically regulating multiple pathways closely associated with EBV infection, including PD-L1/PD-1 pathway, PI3K-Akt signaling pathway and NF-κB signaling pathway. This study provides theoretical basis and experimental clues for further elucidating the antiviral mechanism of YYJ18, and also offers reference for the research and development of multi-target anti-EBV drugs derived from natural products.